An interventional study of Bright light therapy(High light intensity) and Bright light therapy(Low light intensity) in Depressive Disorder, Major, sponsored by Peking University Sixth Hospital. Recruiting at 3 sites in China. Open to participants aged 13 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Peking University Sixth Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 207 studies in Depressive Disorder, Major with a site in China — 75 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.
Among the 207 studies in Depressive Disorder, Major with a site in China, this one is the 69th largest by planned enrollment of the 174 interventional ones that give a count, is one of 23 that started in 2025, is one of 100 with no phase, reaches primary completion later than 37 of the 76 other live ones, and was the 158th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →75 of the 207 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:
Qilu Hospital of Shandong University · Sites in China
Ages 11–19
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
Eli Lilly and Company · Sites in China, United States, Australia and 12 more countries
Ages 18–75
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
Guo Wenbin · Sites in China
Ages 18–45
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
207 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 24 · Phase 3 20 · Phase 4 19
First in 2004; this study’s year is marked. 23 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 168 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 120 across the 174 interventional studies, 240 across the 33 observational. Of the 77 that completed or were terminated, 8 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 207 have an industry lead sponsor. The 10 most frequent:
Peking University Sixth Hospital is the lead sponsor of 19 studies on the registry; 7 are open to participants now.
Peking University Sixth Hospital has 6 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
21 of the studies in Depressive Disorder, Major with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04984512Phase 3Sunshine Lake Pharma Co., Ltd.The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder | 2027-07 |
| NCT06913309Peking University Sixth HospitalClinical Efficacy, Safety, and Applicability of Home-based Bright Light Therapy in Outpatient Adolescents With Major Depressive Disorder | 2026-11-30 |
| NCT06409325Shanghai Mental Health CenterEffectiveness of MST Versus ECT for Major Depressive Episode | 2026-12-30 |
| NCT07873060Qilu Hospital of Shandong UniversityComparing 10 Hz rTMS and iTBS for Adolescent Depression | 2026-12-31 |
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 207 studies in Depressive Disorder, Major with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Major Depressive Disorder (MDD) is a chronic disease characterized by a high prevalence, low cure rate, and significant disability. Globally, depression is recognized as the leading cause of illness and disability among children and adolescents. Bright light therapy (BLT) has been established as an effective treatment for seasonal affective disorder and has demonstrated considerable efficacy in adult patients with MDD. However, its application in adolescent patients with MDD remains largely unexplored. The aim of this clinical trial is to evaluate the clinical efficacy, onset time, safety, and applicability of BLT in adolescents with MDD and to explore the potential neural mechanisms by which BLT enhances emotional and cognitive function in this population. This is a multicenter, randomized, controlled, double-blind study. It will involve adolescents aged 13 to 17 who are either untreated or have been stable on medication for at least one week. Adolescents with MDD will be randomly assigned to one of three groups: a high-intensity bright white light intervention group, a medium-intensity bright white light intervention group, and a placebo control group receiving dim red light. Each group will undergo four weeks of light exposure, six days per week, for 40 minutes daily between 6:30 and 10:00 AM. During the light exposure period, follow-up assessments will be conducted every weekend, and participants will be followed for two weeks after the completion of light exposure.The primary outcome will be the change in total scores on the 17-item Hamilton Rating Scale for Depression (HAMD-17) from baseline to week 4. Secondary outcomes will include response and remission rates, time to onset, maintenance of efficacy, self-reported depressive symptoms, sleep quality, cognitive function, anxiety, irritability, suicidal ideation, non-suicidal self-injury, self-efficacy, and the overall safety profile of BLT.
Additionally, the study will include healthy adolescent controls and collect functional Near-Infrared Spectroscopy (fNIRS) from both the adolescent participants with major depressive disorder and the healthy controls at baseline. The fNIRS and MRI data will also be collected from the adolescent participants with MDD at the end of the intervention, in order to investigate the potential neural mechanisms by which light therapy alleviates depressive symptoms in adolescents.
The inclusion and exclusion criteria for MDD patients:
inclusion criteria
exclusion criteria
The inclusion and exclusion criteria for Health controls
Inclusion criteria
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this study, participants randomly assigned to the intervention group will receive bright white light therapy interventions with light intensities of 10000 lux. The intervention plan is to receive 40 minutes of light therapy from 6:30-10:00 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 45cm from the light source.
Device: Bright light therapy(High light intensity)
In this study, participants randomly assigned to the intervention group will receive bright white light therapy interventions with light intensities of 5000 lux. The intervention plan is to receive 40 minutes of light therapy from 6:30-10:00 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source.
Device: Bright light therapy(Low light intensity)
In this study, participants randomly assigned to the placebo-controlled group will receive dim red light therapy interventions with light intensities of 100 lux. The placebo-controlled intervention plan is to receive 40 minutes of red light therapy from 6:30-10:00 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source.
Device: Dim red light placebo-controlled intervention
In this study, we will utilize the optocoupler-controllable light source, a product jointly developed by the School of Physics at Peking University and Peking University Sixth Hospital, which granted a national patent in China, for the purpose of intervention. Participants randomly assigned to the high light density intervention group will receive bright white light therapy interventions with light intensities of 10000 lux, and the main wavelength of light source is 476.4nm. The intervention plan is to receive 40 minutes of light therapy from 6:30-10:00 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source.
In this study, we will utilize the optocoupler-controllable light source, a product jointly developed by the School of Physics at Peking University and Peking University Sixth Hospital, which granted a national patent in China, for the purpose of intervention. Participants randomly assigned to the low light density intervention group will receive bright white light therapy interventions with light intensities of 5,000 lux,and the main wavelength of light source is 476.4nm. The intervention plan is to receive 40 minutes of light therapy from 6:30-10:00 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source.
In this study, participants randomly assigned to the placebo-controlled group will receive dim red light therapy interventions with light intensities of 100 lux, and the main wavelength of light source is 690.4nm. The placebo-controlled intervention plan is to receive 40 minutes of red light therapy from 6:30-10:00 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source.
Hamilton Depression Rating Scale-17(HAMD-17)
The HAMD-17, developed by Hamilton in 1960, remains one of the most authoritative and widely utilized clinician-rated instruments for assessing depressive severity41. The Chinese version of the HAMD-17 has demonstrated satisfactory internal consistency (Cronbach's alpha = 0.714) and robust concurrent validity. The HAMD-17 assessment comprises 17 items; items 8, 9, and 11 are scored through structured behavioural observation, while the remaining items are primarily assessed via patient self-report during semi-structured interviews. Scoring utilized a five-point Likert scale for the majority of items (1-7, 10, 12-17), with exceptions employing a three-point scale for items 4-6 and 16. Total scores are derived from the summation of all item scores, with higher values indicating greater depressive severity.
Time frame: baseline,7 days after the intervention begin,14 days after the intervention begin,21 days after the intervention begin,28 days after the intervention begin,7 days after the intervention accomplished,14 days after the intervention accomplished
Generalized Anxiety Disorder-7(GAD-7)
The GAD-7, developed by Spitzer et al. in 2006, is a brief self-administered screening questionnaire evaluating the severity of anxiety symptoms. It consists of 7 items rated on a 4-point Likert scale from 0 (not at all) to 3 (nearly every day). Total scores range from 0 to 21, with higher scores reflecting greater anxiety severity. The Chinese version of the GAD-7 has demonstrated excellent psychometric properties, exhibiting robust internal consistency (Cronbach's α = 0.93-0.95) among large Chinese adolescent cohorts.
Time frame: baseline,7 days after the intervention begin,14 days after the intervention begin,21 days after the intervention begin,28 days after the intervention begin,7 days after the intervention accomplished,14 days after the intervention accomplished
Quick Inventory of Depressive Symptomatology-Self-Report(QIDS-SR)
The QIDS-SR, first developed and validated by Rush and colleagues in 2003, is a DSM-IV-based self-report tool specifically designed to assess depressive symptomatology over a seven-day recall period42. The QIDS-SR16 has been validated as a reliable and effective instrument for adolescent outpatients, demonstrating high internal consistency and a robust unidimensional structure. It comprises 16 items, each rated on a 0-3 point scale, with higher total scores indicating greater severity of depressive symptoms. In this study, the QIDS-SR was used to assess self-reported depressive symptoms.
Time frame: baseline, every day of the first two weeks after the intervention begin,21 days after the intervention begin,28 days after the intervention begin,7 days after the intervention accomplished,14 days after the intervention accomplished
Pittsburgh Sleep Quality Inventory (PSQI)
The PSQI, developed by Buysse et al. in 1989 at the University of Pittsburgh, is a self-rated questionnaire designed to assess sleep quality. The Chinese version of the PSQI, validated by Liu et al., demonstrated high internal consistency with a Cronbach's alpha of 0.84 and excellent test-retest reliability with an r value of 0.81 over a two-week period. It comprises nine items: the first four are open-ended, and the remaining five are multiple-choice, with Item 5 containing ten sub-items. These items collectively evaluate seven sleep components, each scored 0-3, yielding a global score ranging from 0 to 21, with higher scores indicating poorer sleep quality.
Time frame: baseline,7 days after the intervention begin,14 days after the intervention begin,21 days after the intervention begin,28 days after the intervention begin,7 days after the intervention accomplished,14 days after the intervention accomplished
Hopkins Verbal Learning Test-Revised (HVLT-R)
HVLT-R is a widely used neuropsychological assessment tool designed to evaluate verbal memory and cognitive function. Developed by J. Brandt and Benedict in 2001, the HVLT-R consists of a list of 12 nouns divided into three semantic categories (e.g., dwelling places, four-legged animals, and precious stones), with four words per category. The assessment involves three learning trials, where participants are presented with the list of words and are asked to recall as many words as possible immediately after each presentation. Additionally, there is a delayed recall trial, where participants are asked to recall the words after a delay of 20-25 minutes. The scoring principle is based on the number of correctly recalled words during each learning trial and the delayed recall trial. The total scores of the three learning trials and the delayed recall trial were computed to represent verbal learning and memory function.
Time frame: baseline, 14 days after the intervention begin, 28 days after the intervention begin,14 days after the intervention accomplished
Brief Visuospatial Memory Test-Revised (BVMT-R)
Brief Visuospatial Memory Test-Revised is a neuropsychological assessment tool designed to evaluate visual spatial memory. Developed by researchers including Barr, Morrison, Zaroff, and Devinsky in 2004, the BVMT-R consists of six geometric figures presented in a 2x3 array, serving as the stimuli for the test. The assessment involves three learning trials, where participants are shown the stimuli for 10 seconds and are then asked to draw as many of the figures as possible in the correct locations on a response sheet. After a delay of approximately 25 minutes, a delayed recall trial is administered, followed by a recognition trial where participants are asked to identify the original geometric figures among a set of 12. The scoring principle is based on the number of correctly recalled and recognized figures, reflecting participants' visuospatial memory ability.
Time frame: baseline, 14 days after the intervention begin, 28 days after the intervention begin, 14 days after the intervention accomplished
Color Trails Test (CTT)
The Color Trails Test (CTT) is a neuropsychological assessment tool specifically designed to minimize cultural and linguistic biases by using colors instead of letters. The test consists of two parts: CTT-1 and CTT-2, each preceded by a brief practice session. 1. CTT-1: The examinee is required to connect circles numbered 1 through 25 in ascending order as quickly as possible. In this part, all circles are of a uniform color (typically yellow or pink). This part primarily assesses the examinee's psychomotor speed and visual scanning abilities. 2. CTT-2: This part consists of 50 circles, containing two sets of numbers from 1 to 25. Each number appears twice: once in a pink circle and once in a yellow circle. The examinee must connect the numbers in ascending order (1-2-3...) while simultaneously alternating between the two colors (e.g., 1-Pink, 2-Yellow, 3-Pink, 4-Yellow...). This part serves as a sensitive measure of sustained attention, divided attention, and cognitive flexibility.
Time frame: baseline,14 days after the intervention begin,28 days after the intervention begin,14 days after the intervention accomplished
The General Self-Efficacy Scale (GSES)
The GSES, based on Bandura's self-efficacy theory, originally developed by Schwarzer and Jerusalem in 1981, and revised for the Chinese population by Wang et al., evaluates an individual's perceived ability to cope with setbacks or challenges. It comprises 10 items rated on a 4-point Likert scale (1-4), with total scores ranging from 10 to 40; higher scores indicate greater self-efficacy.
Time frame: baseline, 7 days after the intervention begin, 14 days after the intervention begin, 21 days after the intervention begin, 28 days after the intervention begin, 7 days after the intervention accomplished, 14 days after the intervention accomplished
Young Mania Rating Scale (YMRS)
Developed by Young et al. in 1978, the YMRS is a widely utilized clinician-administered tool designed to quantify the severity of manic symptoms. It comprises 11 items evaluating domains such as mood elevation, increased motor activity, irritability, speech, thought content, and sleep disturbance. Four items (irritability, speech, thought content, and disruptive/aggressive behavior) are graded on a 0 to 8 Likert scale to capture a broader range of severity, while the remaining seven items are graded on a 0 to 4 scale. Total scores range from 0 to 60, with higher scores indicating greater manic severity.
Time frame: baseline, 7 days after the intervention begin, 14 days after the intervention begin, 21 days after the intervention begin, 28 days after the intervention begin, 7 days after the intervention accomplished, 14 days after the intervention accomplished
Asberg Side-Effect Rating Scale for Antidepressants(SERS)
Originally introduced by Åsberg et al. in 1978, the Side Effects Rating Scale (SERS) is a standardized instrument employed to assess the burden of common antidepressant-induced adverse events. Each SERS item is rated on a 0-3-point scale with the following criteria: (0) absent; (1) mild; (2) moderate; (3) severe. Outcome measures include individual item scores and total scores, with higher scores indicating greater side effect severity. This study utilized the SERS to assess both the alleviation of somatic symptoms and the potential adverse effects associated with the light therapy intervention.
Time frame: baseline, 7 days after the intervention begin, 14 days after the intervention begin, 21 days after the intervention begin, 28 days after the intervention begin, 7 days after the intervention accomplished, 14 days after the intervention accomplished
Adolescent Irritability Rating Scale (ARI)
Developed by Stringaris et al. in 2012 to measure irritability in youths, the ARI evaluates the threshold, frequency, and duration of irritable manifestations. The 7-item scale is rated from 0 (not true) to 2 (certainly true). The total score is the sum of the first six items, while the seventh item independently assesses impairment. The Chinese adaptation of the ARI has demonstrated good convergent and concurrent validity, alongside robust reliability among adolescents.
Time frame: baseline, 7 days after the intervention begin, 14 days after the intervention begin, 21 days after the intervention begin, 28 days after the intervention begin, 7 days after the intervention accomplished, 14 days after the intervention accomplished
Stroop Color-Word Test (SCWT)
The SCWT was developed by Professor Stroop in 1935 to evaluate subjects' executive functions. The test is a measure of selective attention and the degree of inhibition of irrelevant information in executive functioning. It consists of three main parts: reading words (Stroop-w), color naming (Stroop-c), and color-word interference (Stroop-cw), which require subjects to accurately and quickly read the words or the colors, respectively, as required.
Time frame: baseline, 14 days after the intervention begin, 28 days after the intervention begin, 14 days after the intervention accomplished
Ottawa Self-Injury Inventory (OSI)
Developed by Nixon and Cloutier in the late 1990s, the OSI comprehensively assesses non-suicidal self-injury (NSSI) behaviors and addictive features. The Chinese OSI demonstrated favorable reliability and validity in adolescent cohorts. NSSI frequency over the past month is scored on a 4-point scale, whereas longer-term frequencies (e.g., past 6 months, past year) use a 5-point scale. In this study, the OSI items were employed to evaluate NSSI/suicide attempt frequency, severity, history, onset age, emotional triggers, and disclosure.
Time frame: baseline, 7 days after the intervention begin, 14 days after the intervention begin, 21 days after the intervention begin, 28 days after the intervention begin, 7 days after the intervention accomplished, 14 days after the intervention accomplished
Response rate
Response will be defined as a ≥50% reduction in the total score of the HAMD-17 from baseline.
Time frame: baseline, 28 days after the intervention begin
Remission rate
Remission will be defined as achieving a HAMD-17 score of ≤7 points at T4.
Time frame: 28 days after the intervention begin
Hamilton Anxiety Rating Scale (HAMA)
Originally developed by Hamilton in 195944, the HAMA is a classic clinician-administered questionnaire assessing both somatic and psychic anxiety severity. The 14-item instrument captures psychic anxiety (items 1-6, 14) and somatic anxiety (items 7-13). Each item is rated on a 5-point Likert scale from 0 (absent) to 4 (very severe), with higher total scores indicating more severe clinical anxiety. The construct validity and reliability of the Chinese HAMA adaptation have been rigorously established in domestic psychometric studies.In this study, the HAMA was used to assess the severity of anxiety symptoms.
Time frame: baseline,7 days after the intervention begin,14 days after the intervention begin,21 days after the intervention begin,28 days after the intervention begin,7 days after the intervention accomplished,14 days after the intervention accomplished
Sleep diary
The sleep diary used in this study was adapted from the National Sleep Foundation Sleep Diary (MSFSD) and consists of two sections: morning and evening entries. Morning entries assess bedtime, wake-up time, sleep latency, number of nocturnal awakenings, subjective morning alertness, total sleep duration, and factors disrupting sleep. Evening entries assess daytime nap frequency and duration, physical activity and outdoor exposure, caffeine intake, pre-sleep dietary intake and hydration, electronic device usage before bedtime, and activities during the hour preceding sleep.
Time frame: Recorded daily during the intervention
Semi-structured interviews
Each interview will last around 30 minutes and will be conducted via secure videoconferencing platforms. The interview guide will explore participants' experiences with home-based BLT, including perceived impacts on daily life, expectations of treatment efficacy, attitudes toward home-based delivery, and willingness to recommend BLT to adolescents with similar needs.Semi-structured interviews were used to assess the applicability of BLT.
Time frame: After the intervention period.
fNIRS indicators
During the resting-state recording, subjects will be instructed to keep their eyes open, remain awake, maintain a relaxed state, and refrain from engaging in thoughts that could influence their mood. In each run, eight minutes of resting-state fNIRS data are acquired. The experimental task was based on a standardized Chinese VFT paradigm and comprised three phases: a 30-second baseline rest, a 60-second active word-generation period, and a 70-second recovery phase53. During the rest phases, participants were instructed to fixate on a central point while counting aloud from 1 to 5. During the task, participants are instructed to generate compound words using the Chinese characters '白' (white), '天' (sky), and '大' (big), which are presented sequentially. Resting-state functional connectivity and task-related cortical activation levels were extracted as outcome measures.
Time frame: baseline, 28 days after the intervention begin
the Continuous Performance Test-Identical Pairs (CPT-IP)
The CPT-IP was administered using the CBCT software. Participants were instructed to press the response key as quickly as possible when specific "target stimuli"-i.e., animal pictures-appeared on the screen. When distractor stimuli were presented, participants were required to withhold their keypress response. This test is primarily used to assess participants' sustained attention, vigilance, and impulse control.
Time frame: baseline, 14 days after the intervention begin, 28 days after the intervention begin, 14 days after the intervention accomplished
Trail Making Test Part A (TMT-A)
The Trail Making Test Part A (TMT-A) requires the examinee to connect 25 randomly distributed circles in ascending numerical order (1-2-3...) as quickly as possible without lifting the pen, serving as a standardized measure of visual scanning, psychomotor speed, and motor coordination.
Time frame: baseline, 14 days after the intervention begin, 28 days after the intervention begin, 14 days after the intervention accomplished
Plan to share: Yes — As the research is still in the recruitment stage and has not yet reached the data analysis phase, no usable dataset has been generated yet. De-identified individual participant data (IPD) underlying the results reported in this article will be available beginning 6 to 12 months after publication.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will become available 6 to 12 months after the publication of the primary trial results and will remain accessible for up to 2 years (24 months).
Access criteria: Eligible Applicants: Access will be granted to qualified researchers who provide a methodologically sound research proposal and whose request has been approved by the study's Primary Investigators or an independent review committee. Purpose of Data Sharing: The data will be shared to facilitate the achievement of scientific objectives specified in the approved research proposal. Application Process and Workflow: Submission of Proposal: Interested applicants are required to submit a formal research proposal and a Statistical Analysis Plan (SAP) to the corresponding author via email at lvxiaozhen@bjmu.edu.cn. Review and Agreement: Upon approval of the proposal, the data requestor must sign a formal Data Access Agreement (DAA). this agreement ensures strict compliance with data security, ethical standards, and participant privacy protections.
Started Apr 2025 (actual). Primary completion is estimated for Nov 2026, 19 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 19 months is below that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Mar 2025 → Apr 2025, primary completion Jun 2026 → Nov 2026 and completion Jun 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Sixth Hospital